Health Sciences Acquisitions Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
The last earnings update was 248 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Immunovant. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Immunovant's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immunovant has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Capital Markets industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Immunovant's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Immunovant's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Immunovant's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if Immunovant is high growth as no earnings estimate data is available.
Unable to determine if Immunovant is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Immunovant's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Roderick T. Wong, also known as Rod, MD, is President and Chief Executive Officer of Health Sciences Acquisitions Corp since January 2019 and its Director since December 2018. He is Managing Partner and Chief Investment Officer at RTW Investments LP. Dr. Wong founded the firm on March 1, 2010. He is Chairman of the Board of Health Sciences Acquisitions Corp. He has over a decade of experience as a life sciences Fund Manager. Prior to this, from March 2005 to January 2009, Dr. Wong was employed at Davidson Kempner Capital Management LLC. He started managing a healthcare book in 2005. Dr. Wong is a Healthcare Analyst at Sigma Capital Management, LLC. He researched biotechnology companies at Cowen Group inc., where he is an Chief Executive Officer. Dr. Wong is a Director at RXi Pharmaceuticals Corporation. He is Chairman of Rocket Pharmaceuticals, Inc. since January 2018. He is a Director of Penwest Pharmaceuticals Co. until 2010. Dr. Wong isn Adjunct Assistant Professor at the New York University Stern Business School. He has completed medical training. He simultaneously received an MD from the University of Pennsylvania Medical School and an MBA from Harvard Business School, and graduated Phi Beta Kappa with a BS in Economics from Duke University.
Insufficient data for Rod to compare compensation growth.
Insufficient data for Rod to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Immunovant management team is less than 2 years, this suggests a new team.
VP of Operations
Vice President of Corporate Strategy & Corporate Communications
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Immunovant board of directors is less than 3 years, this suggests a new board.
Board of Directors
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Health Sciences Acquisitions Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on businesses in the healthcare and healthcare-related industries in North America or Europe. The company was founded in 2018 and is based in New York, New York.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.